FOLR1 and ovarian carcinoma: FRα is frequently overexpressed in a range of epithelial malignancies, including approximately 35–70% of breast cancers, 15–75% of lung cancers, 20–50% of endometrial cancers, and 75–90% of ovarian cancers [2,3,4].